Case File
efta-01773938DOJ Data Set 10OtherEFTA01773938
Date
Unknown
Source
DOJ Data Set 10
Reference
efta-01773938
Pages
5
Persons
0
Integrity
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
From:
Barrett, Paul S
Sent:
Monday, October 3, 2011 1:53 PM
To:
Jeffrey epstein
Cc:
Ens, Amanda
Subject:
RE: Update
Jeffrey
We are now up $1.1MM for the year and down $5.8MM since inception.
We are still seeing more funding stress in European banks. We own 2.5MM face of the MG Pfds which I think we should
sell. The company tried to call these at par earlier in the year but the Dutch govt rejected this request and the long
spread duration embedded here makes us think we should cut. We paid 97 for them. Would work 72 to sell.
In the US we should sell the 2MM of our Wachovia Pfds we own. Same story —just looking to reduce financial pfd
exposure. Paid 93.50. Would work 83.00 to sell.
We have protection on half our MS and Telefonica positions.
Corn was down 5% on Friday's inventory report. We are still up $1.5MM on this position. I think we spend some of these
profits on a 1 month put. If China fears accelerate there could be significant downside from here and would like to
protect these gains.
Let me know
Paul
EFTA_R1_00087071
EFTA01773938
Paul Barrett, CFA
Managing Director
Global Investment Opportunities Group
JPMorgan Private Bank
From: jeffrey epstein (mailto:[email protected]
Sent: Tuesday, September 27, 2011 2:26 PM
To: Barrett, Paul S
Subject: Re: Update
Ok
Sorry for all the typos .Sent from my iPhone
On Sep 27, 2011, at 8:23 PM, "Barrett, Paul S"
wrote:
Jeffrey
I think we should take advantage of the recent rally to trim some positions that either have limited upside (like
our Barclays Pfds and Citi Pfds) or are at risk for further downside if Europe does not ratify the expanded EFSF.
2
EFTA_R1_00087072
EFTA01773939
Recommendation:
- trim our CIT from 10MM to 5MM. Would sell 52.5MM of both the 2016 and the 2017 maturity. We are up on
both positions
- collar V2 our MS exposure for 1 month. This would entail buying a 14 put and selling a 17 call. Cost around
10c/share
- collar 'A out Telefonica position for 1 month. 13.50/15 collar. Cashless.
I will call you to discuss.
Paul
Paul Barrett, CFA
Managing Director
Global Investment Opportunities Group
JPMorgan Private Bank
From: Barrett, Paul S
Sent: Wednesday, September 21, 2011 3:52 PM
To: 'Jeffrey Epstein'
Subject: Update
Hi Jeffrey
3
EFTA_R1_00087073
EFTA01773940
We are still doing some more credit work before we close the $5MM Harrah's note.
Since the end of August the account is down around $2.7MM (was flat at the end of Aug).This translates into -
$6.98MM for 2010 and +$4.25MM YTD for 2011.
This has been due to (changes since End of August):
SG0 down 5% ($500K)
INR down 5% ($500K
We switched both of these forwards into options so we have limited downside from here on out
CADJPY down 150K [We are long the 83.25 CAD Call and Short the 76.00 Put with a knock in at 71; spot at 76.50;
knock in 7% away)
Oil call down 140K
Corn down 600K
ING Pfds down 200K
MS Note knocked in down 140K
Telefonica note down 300K [Stock is trading below 2009 lows; only 35% of their revenue comes from Spain;
would HOLD]
I would like to reduce further downside.
I think the cheapest protection out there remains buying CDS on Asia. For example Indonesia CDS costs 220bps.
It got as wide as 1200bps in 2008. It feels like Asian credit spreads remain one of the few things that have not moved
and could provide some cheaper tail risk if things deteriorate further.
Financial Pfds remain our largest notional exposure (around $20MM). I think we should reduce some exposure
here. Would involve selling some of JPM, Barclays and Citigroup. BAC and WFC was downgraded today and would also
trim those positions.
Do you have time to discuss?
4
EFTA_R1_00087074
EFTA01773941
Paul
Paul Barrett, CFA
Managing Director
Global Investment Opportunities Group
JPMorgan Private Bank
This email is confidential and subject to important disclaimers and conditions including on offers for the
purchase or sale of securities, accuracy and completeness of information, viruses, confidentiality, legal privilege, and
legal entity disclaimers, available at http://www.jpmorgan.com/pages/disclosures/email.
This email is confidential and subject to important disclaimers and conditions including on offers for the purchase or sale
of securities, accuracy and completeness of information, viruses, confidentiality, legal privilege, and legal entity
disclaimers, available at http://www.jpmorgan.com/pages/disclosures/email.
5
EFTA_R1_00087075
EFTA01773942
Technical Artifacts (2)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Email
[email protected]URL
http://www.jpmorgan.com/pages/disclosures/emailRelated Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.